News

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...
The Bakersfield Californian2d
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin ...
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced ...
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...
pharmaphorum3d
Boehringer says R&D pipeline is the best in its long history
In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...
C&EN2d
Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres
⊥ ∥ Departments of Therapeutic Discovery, and ⊥ Oncology Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States # Department of Therapeutic Discovery, Amgen Inc., ...